Following today’s hearing in the NGAL cutoff opposition proceedings, the
European Patent Organization has exceptionally chosen not to reach a final
decision. The proceedings will be continued on the basis of written
submissions. BioPorto has not received information about the timing of further
proceedings. BioPorto’s patent remains fully valid during the proceedings. 



For further information, please contact:

Peter Mørch Eriksen, CEO

Christina Thomsen, Investor Relations
Telephone +45 4529 0000, e-mail investor@bioporto.com